Literature DB >> 18596204

Impaired gamma interferon response to Mycobacterium vaccae antigens in patients with cavitary pulmonary tuberculosis.

Elisabeth Rodríguez-Güell1, Gemma Agustí, Mercè Corominas, Marina Luquin, Esther Julián.   

Abstract

The ability of tuberculosis patients to recognize Mycobacterium vaccae-specific antigens before starting chemotherapy and according to disease severity was analyzed. We report that the M. vaccae cell wall skeleton fraction triggers more enhanced cytokine production than the whole bacterium. Moreover, a tendency was observed for a lower gamma interferon/interleukin-10 ratio in patients with cavitary disease induced by M. vaccae antigens.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18596204      PMCID： PMC2546679          DOI： 10.1128/CVI.00131-08

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN： 1556-679X


  15 in total

1.  T lymphocyte phenotypic profile in lung segments affected by cavitary and non-cavitary tuberculosis.

Authors:  G Mazzarella; A Bianco; F Perna; D D'Auria; E Grella; E Moscariello; A Sanduzzi
Journal:  Clin Exp Immunol       Date:  2003-05       Impact factor: 4.330

2.  Decreased in vitro interferon-gamma production in patients with cavitary tuberculosis on chest radiography.

Authors:  Huang-Pin Wu; Chung-Ching Hua; Duen-Yau Chuang
Journal:  Respir Med       Date:  2006-06-06       Impact factor: 3.415

3.  Clinical correlates of interferon gamma production in patients with tuberculosis.

Authors:  A Sodhi; J Gong; C Silva; D Qian; P F Barnes
Journal:  Clin Infect Dis       Date:  1997-09       Impact factor: 9.079

4.  Immunological consequences of three doses of heat-killed Mycobacterium vaccae in the immunotherapy of tuberculosis.

Authors:  Diana Dlugovitzky; Gladys Fiorenza; Miguel Farroni; Christine Bogue; Cynthia Stanford; John Stanford
Journal:  Respir Med       Date:  2005-11-08       Impact factor: 3.415

5.  Dynamic changes in pro- and anti-inflammatory cytokine profiles and gamma interferon receptor signaling integrity correlate with tuberculosis disease activity and response to curative treatment.

Authors:  Edhyana Sahiratmadja; Bachti Alisjahbana; Tjitske de Boer; Iskandar Adnan; Anugrah Maya; Halim Danusantoso; Ronald H H Nelwan; Sangkot Marzuki; Jos W M van der Meer; Reinout van Crevel; Esther van de Vosse; Tom H M Ottenhoff
Journal:  Infect Immun       Date:  2006-12-04       Impact factor: 3.441

Review 6.  Immune responses to tuberculosis in developing countries: implications for new vaccines.

Authors:  Graham A W Rook; Keertan Dheda; Alimuddin Zumla
Journal:  Nat Rev Immunol       Date:  2005-08       Impact factor: 53.106

7.  Effect of Mycobacterium vaccae (SRL172) immunotherapy on radiographic healing in tuberculosis.

Authors:  J L Johnson; A J Nunn; P B Fourie; L P Ormerod; R D Mugerwa; A Mwinga; C Chintu; B Ngwira; P Onyebujoh; A Zumla
Journal:  Int J Tuberc Lung Dis       Date:  2004-11       Impact factor: 2.373

8.  Influence of disease severity on nitrite and cytokine production by peripheral blood mononuclear cells (PBMC) from patients with pulmonary tuberculosis (TB).

Authors:  D Dlugovitzky; M L Bay; L Rateni; G Fiorenza; L Vietti; M A Farroni; O A Bottasso
Journal:  Clin Exp Immunol       Date:  2000-12       Impact factor: 4.330

9.  The production of a new extracellular putative long-chain saturated polyester by smooth variants of Mycobacterium vaccae interferes with Th1-cytokine production.

Authors:  Elisabeth Rodríguez-Güell; Gemma Agustí; Mercè Corominas; Pere-Joan Cardona; Isidre Casals; Teodor Parella; Marco-Antonio Sempere; Marina Luquin; Esther Julián
Journal:  Antonie Van Leeuwenhoek       Date:  2006-05-02       Impact factor: 2.271

Review 10.  Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis.

Authors:  John Stanford; Cynthia Stanford; John Grange
Journal:  Front Biosci       Date:  2004-05-01
View more
  1 in total

1.  Impaired M. tuberculosis Antigen-Specific IFN-γ Response without IL-17 Enhancement in Patients with Severe Cavitary Pulmonary Tuberculosis.

Authors:  Lin Fan; Heping Xiao; Guangliang Mai; Bo Su; Joel Ernst; Zhongyi Hu
Journal:  PLoS One       Date:  2015-05-27       Impact factor: 3.240
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.